Tirzepatide vs Retatrutide

Research & educational use only. This content is not medical advice. Consult a qualified healthcare professional before using any peptide compound.

Tirzepatide and Retatrutide are both glp1 peptides that come up together constantly. This is a side-by-side comparison on the data that actually matters — evidence tier, FDA status, human trials, and how to source each safely — not hype. It is for research and educational purposes only.

Tirzepatide vs Retatrutide: side-by-side

TirzepatideRetatrutide
Evidence tierTier 1Tier 1
FDA statusFDA ApprovedPhase 3 Trials
Human RCTs82
Subjects enrolled13,000700
Animal studies1510
Categoryglp1glp1
Half-lifeApproximately 5 days, enabling once-weekly administration.Supports once-weekly administration.
Community logs10

Key differences

Both Tirzepatide and Retatrutide sit at the same evidence tier (Tier 1), so neither has a clear edge in how strong its human data is. Tirzepatide is FDA approved for specific uses, while Retatrutide is phase 3 trials and treated as a research compound in the US.

Tirzepatide has 8 human trials on record (13,000 subjects) versus Retatrutide's 2 (700 subjects). Evidence tiers are a shorthand for how strong that human data is — see our guide to understanding peptide evidence tiers for how to weigh them.

What is Tirzepatide?

Tirzepatide is a dual GIP and GLP-1 receptor agonist approved by the FDA (as Mounjaro for type 2 diabetes and Zepbound for chronic weight management). It is supported by large phase 3 randomized controlled trials demonstrating significant glycemic and weight outcomes. It is a prescription medication; non-prescription… Full Tirzepatide breakdown →

What is Retatrutide?

Retatrutide is an investigational triple agonist of the GIP, GLP-1, and glucagon receptors being developed for obesity and type 2 diabetes. Phase 2 randomized controlled trials reported among the largest weight reductions seen for an incretin-based therapy, and phase 3 trials are underway. It is not FDA-approved and… Full Retatrutide breakdown →

Where to buy Tirzepatide or Retatrutide safely

Both are sold by research-chemical suppliers, not pharmacies, so the source matters as much as the compound. Before buying either, vet sellers on third-party lab testing and enforcement history in the ranked directory of trusted peptide sellers — or jump straight to vetted sources for Tirzepatide or Retatrutide. PeptidesHub does not sell either compound.

Frequently asked questions

Tirzepatide and Retatrutide are both glp1 peptides. Both Tirzepatide and Retatrutide sit at the same evidence tier (Tier 1), so neither has a clear edge in how strong its human data is. Tirzepatide is FDA approved for specific uses, while Retatrutide is phase 3 trials and treated as a research compound in the US. See each compound's full evidence breakdown for the underlying studies.